Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review

Autor: Seitaridou Y., Dimitrova M., Chamova T., Kamusheva M., Panayotov P.

Publikováno v: Acta Medica Bulgarica, Vol 49, Iss 4, Pp 69-80 (2022)

Multiple Sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system, characterized by demyelination, axonal damage and progressive disability. This literature review aims to provide an overview of cost-effectivene

Externí odkaz: https://doaj.org/article/b500e5ef549d4a76b06bf3a33f5d791e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece.

Autor: Seitaridou Y; Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria., Tsekov I; Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria., Kamusheva M; Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria., Dimitrova M; Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria., Petrova G; Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria.

Publikováno v: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2022 Mar; Vol. 22 (2), pp. 241-246. Date of Electronic Publication: 2021 Sep 22.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.